{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T17:47:32Z","timestamp":1786988852983,"version":"build-2736575974"},"reference-count":177,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["esmoopen.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["ESMO Open"],"published-print":{"date-parts":[[2024,7]]},"DOI":"10.1016\/j.esmoop.2024.103484","type":"journal-article","created":{"date-parts":[[2024,6,19]],"date-time":"2024-06-19T14:56:39Z","timestamp":1718808999000},"page":"103484","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Bone health and body composition in prostate cancer: Meet-URO and AIOM consensus about prevention and management strategies"],"prefix":"10.1016","volume":"9","author":[{"given":"M.C.","family":"Cursano","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.A.","family":"Valsecchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Pantano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8906-3785","authenticated-orcid":false,"given":"M.","family":"Di Maio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Procopio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Berruti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5175-7340","authenticated-orcid":false,"given":"F.","family":"Bertoldo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Tucci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"U.","family":"De Giorgi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Santini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amelia","family":"Altavilla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Atzori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe Luigi","family":"Banna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandro","family":"Barni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Umberto","family":"Basso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matteo","family":"Bauckneht","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rossana","family":"Berardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alfredo","family":"Berruti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Bertoldo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Davide","family":"Bimbatti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Boccardo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastiano","family":"Buti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Consuelo","family":"Buttigliero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Orazio","family":"Caffo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabio","family":"Calabr\u00f2","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlo","family":"Cattrini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Cellini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincenza","family":"Conteduca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Concetta","family":"Cursano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"De Feo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ugo","family":"De Giorgi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Di Lorenzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimo","family":"Di Maio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marilena","family":"Di Napoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Ermacora","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Fornarini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucia","family":"Fratino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vittorio","family":"Fusco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Gernone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toni","family":"Ibrahim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaetano","family":"Lanzetta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Malgeri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Maruzzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Masini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlo","family":"Messina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Mosca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emanuele","family":"Naglieri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franco","family":"Nol\u00e8","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cinzia","family":"Ortega","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Palermo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Pantano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veronica","family":"Prati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Procopio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pasquale","family":"Rescigno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michela","family":"Roberto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabrina","family":"Rossetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giandomenico","family":"Roviello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniele","family":"Santini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Stellato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosa","family":"Tambaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilaria","family":"Toma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcello","family":"Tucci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna Amela","family":"Valsecchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Verzoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisa","family":"Zanardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo Andrea","family":"Zucali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"suppl 5","key":"10.1016\/j.esmoop.2024.103484_bib2","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/bju.12964","article-title":"Adverse effects of androgen-deprivation therapy in prostate cancer and their management","volume":"115","author":"Rhee","year":"2015","journal-title":"BJU Int"},{"key":"10.1016\/j.esmoop.2024.103484_bib3","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1016\/j.eururo.2014.07.010","article-title":"Adverse effects of androgen deprivation therapy and strategies to mitigate them","volume":"5","author":"Nguyen","year":"2015","journal-title":"Eur Urol"},{"key":"10.1016\/j.esmoop.2024.103484_bib4","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1186\/s12885-015-1843-3","article-title":"Risk of fracture in men with prostate cancer on androgen deprivation therapy: a population-based cohort study in New Zealand","volume":"15","author":"Wang","year":"2015","journal-title":"BMC Cancer"},{"issue":"11","key":"10.1016\/j.esmoop.2024.103484_bib5","doi-asserted-by":"crossref","first-page":"2388","DOI":"10.1002\/cncr.24283","article-title":"Review of major adverse effects of androgen-deprivation therapy in men with prostate cancer","volume":"115","author":"Taylor","year":"2009","journal-title":"Cancer"},{"key":"10.1016\/j.esmoop.2024.103484_bib6","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1053\/hp.2000.6698","article-title":"Metastatic patterns of prostate cancer: an autopsy study of 1,589 patients","volume":"5","author":"Bubendorf","year":"2000","journal-title":"Hum Pathol"},{"key":"10.1016\/j.esmoop.2024.103484_bib7","doi-asserted-by":"crossref","first-page":"v69","DOI":"10.1093\/annonc\/mdv222","article-title":"Cancer of the prostate: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"26","author":"Parker","year":"2015","journal-title":"Ann Oncol"},{"issue":"2","key":"10.1016\/j.esmoop.2024.103484_bib8","doi-asserted-by":"crossref","DOI":"10.1136\/esmoopen-2019-000652","article-title":"Bone health management in the continuum of prostate cancer disease: a review of the evidence with an expert panel opinion","volume":"5","author":"Santini","year":"2020","journal-title":"ESMO Open"},{"key":"10.1016\/j.esmoop.2024.103484_bib9","first-page":"2361","article-title":"Changes in bone mineral density, lean body mass and fat content as measured by dual energy x-ray absorptiometry in patients with prostate cancer without apparent bone metastases given androgen deprivation therapy","volume":"167","author":"Berruti","year":"2002","journal-title":"J\u00a0Urol"},{"key":"10.1016\/j.esmoop.2024.103484_bib10","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1016\/j.urology.2003.10.063","article-title":"Changes in fat and lean body mass during androgen-deprivation therapy for prostate cancer","volume":"4","author":"Smith","year":"2004","journal-title":"Urology"},{"issue":"2","key":"10.1016\/j.esmoop.2024.103484_bib11","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1002\/stem.1857","article-title":"Concise review: the obesity cancer paradigm: exploration of the interactions and crosstalk with adipose stem cells","volume":"33","author":"Strong","year":"2015","journal-title":"Stem Cells"},{"issue":"13","key":"10.1016\/j.esmoop.2024.103484_bib12","doi-asserted-by":"crossref","first-page":"11203","DOI":"10.18632\/oncotarget.3587","article-title":"Esophageal adenocarcinoma and obesity: peritumoral adipose tissue plays a role in lymph node invasion","volume":"6","author":"Trevellin","year":"2015","journal-title":"Oncotarget"},{"issue":"2","key":"10.1016\/j.esmoop.2024.103484_bib13","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1007\/s11154-021-09633-5","article-title":"Mammary gland adipocytes in lactation cycle, obesity and breast cancer","volume":"22","author":"Colleluori","year":"2021","journal-title":"Rev Endocr Metab Disord"},{"issue":"12","key":"10.1016\/j.esmoop.2024.103484_bib14","doi-asserted-by":"crossref","first-page":"2393","DOI":"10.1111\/cas.13415","article-title":"Esophageal adenocarcinoma microenvironment: peritumoral adipose tissue effects associated with chemoresistance","volume":"108","author":"Carraro","year":"2017","journal-title":"Cancer Sci"},{"issue":"10","key":"10.1016\/j.esmoop.2024.103484_bib15","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1007\/s11912-023-01447-9","article-title":"Role of body composition in the prediction of skeletal fragility induced by hormone deprivation therapies in cancer patients","volume":"25","author":"Dalla Volta","year":"2023","journal-title":"Curr Oncol Rep"},{"key":"10.1016\/j.esmoop.2024.103484_bib16","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1056\/NEJMoa041943","article-title":"Risk of fracture after androgen deprivation for prostate cancer","volume":"2","author":"Shahinian","year":"2005","journal-title":"N\u00a0Engl J Med"},{"issue":"27","key":"10.1016\/j.esmoop.2024.103484_bib17","doi-asserted-by":"crossref","first-page":"4426","DOI":"10.1200\/JCO.2007.15.1233","article-title":"Skeletal health after continuation, withdrawal, or delay of alendronate in men with prostate cancer undergoing androgen-deprivation therapy","volume":"26","author":"Greenspan","year":"2008","journal-title":"J\u00a0Clin Oncol"},{"issue":"1","key":"10.1016\/j.esmoop.2024.103484_bib18","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1111\/bju.14015","article-title":"Systematic review and network meta-analysis on the relative efficacy of osteoporotic medications: men with prostate cancer on continuous androgen-deprivation therapy to reduce risk of fragility fractures","volume":"121","author":"Poon","year":"2018","journal-title":"BJU Int"},{"key":"10.1016\/j.esmoop.2024.103484_bib19","doi-asserted-by":"crossref","first-page":"459","DOI":"10.7326\/L17-0702","article-title":"Bone health and bone-targeted therapies for nonmetastatic prostate cancer","volume":"6","author":"Alibhai","year":"2018","journal-title":"Ann Intern Med"},{"issue":"19","key":"10.1016\/j.esmoop.2024.103484_bib20","doi-asserted-by":"crossref","first-page":"4148","DOI":"10.3390\/nu14194148","article-title":"Definition, assessment, and management of vitamin D inadequacy: suggestions, recommendations, and warnings from the Italian Society for Osteoporosis, Mineral Metabolism and Bone Diseases (SIOMMMS)","volume":"14","author":"Bertoldo","year":"2022","journal-title":"Nutrients"},{"issue":"14","key":"10.1016\/j.esmoop.2024.103484_bib21","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1056\/NEJMoa1212299","article-title":"Intermittent versus continuous androgen deprivation in prostate cancer","volume":"368","author":"Hussain","year":"2013","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.esmoop.2024.103484_bib22","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.jbspin.2018.09.017","article-title":"French recommendations for osteoporosis prevention and treatment in patients with prostate cancer treated by androgen deprivation","volume":"1","author":"Briot","year":"2019","journal-title":"Joint Bone Spine"},{"issue":"16","key":"10.1016\/j.esmoop.2024.103484_bib23","doi-asserted-by":"crossref","first-page":"5998","DOI":"10.3390\/ijerph17165998","article-title":"Medication-Related Osteonecrosis of Jaws (MRONJ) prevention and diagnosis: Italian consensus update 2020","volume":"17","author":"Campisi","year":"2020","journal-title":"Int J Environ Res Public Health"},{"issue":"7","key":"10.1016\/j.esmoop.2024.103484_bib24","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1002\/jbmr.4298","article-title":"Prior loss of body mass index, low body mass index, and central obesity independently contribute to higher rates of fractures in elderly women and men","volume":"36","author":"Zheng","year":"2021","journal-title":"J\u00a0Bone Miner Res"},{"issue":"1","key":"10.1016\/j.esmoop.2024.103484_bib25","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.prnil.2018.04.002","article-title":"Sarcopenia is a poor prognostic factor of castration-resistant prostate cancer treated with docetaxel therapy","volume":"7","author":"Ohtaka","year":"2019","journal-title":"Prostate Int"},{"issue":"11","key":"10.1016\/j.esmoop.2024.103484_bib26","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1200\/JCO.2013.51.6500","article-title":"Randomized controlled trial of early zoledronic acid in men with castration-sensitive prostate cancer and bone metastases: results of CALGB 90202 (alliance)","volume":"32","author":"Smith","year":"2014","journal-title":"J\u00a0Clin Oncol"},{"issue":"9810","key":"10.1016\/j.esmoop.2024.103484_bib27","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S0140-6736(11)61226-9","article-title":"Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: results of a phase 3, randomised, placebo-controlled trial","volume":"379","author":"Smith","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.esmoop.2024.103484_bib28","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/S2213-8587(17)30138-9","article-title":"10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension","volume":"7","author":"Bone","year":"2017","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"9768","key":"10.1016\/j.esmoop.2024.103484_bib29","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1016\/S0140-6736(10)62344-6","article-title":"Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study","volume":"377","author":"Fizazi","year":"2011","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.esmoop.2024.103484_bib30","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1186\/s13018-021-02554-8","article-title":"Comparison of denosumab and zoledronic acid for the treatment of solid tumors and multiple myeloma with bone metastasis: a systematic review and meta-analysis based on randomized controlled trials","volume":"16","author":"Jiang","year":"2021","journal-title":"J\u00a0Orthop Surg Res"},{"key":"10.1016\/j.esmoop.2024.103484_bib31","article-title":"A\u00a0real-world study assessing the use of bone-targeted agents and their impact on bone metastases in patients with prostate cancer treated in clinical practice in Europe","volume":"14","author":"Body","year":"2019","journal-title":"J\u00a0Bone Oncol"},{"key":"10.1016\/j.esmoop.2024.103484_bib32","article-title":"Two-year results of a randomised trial comparing 4- versus 12-weekly bone-targeted agent use in patients with bone metastases from breast or castration-resistant prostate cancer","volume":"30","author":"Clemons","year":"2021","journal-title":"J\u00a0Bone Oncol"},{"key":"10.1016\/j.esmoop.2024.103484_bib33","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.1200\/JCO.2008.19.2146","article-title":"Randomized phase II trial of denosumab in patients with bone metastases from prostate cancer, breast cancer, or other neoplasms after intravenous bisphosphonates","volume":"10","author":"Fizazi","year":"2009","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.esmoop.2024.103484_bib34","doi-asserted-by":"crossref","first-page":"2993","DOI":"10.1016\/j.ejca.2012.05.014","article-title":"Randomised phase II\/III study of docetaxel with or without risedronate in patients with metastatic Castration Resistant Prostate Cancer (CRPC), the Netherlands Prostate Study (NePro)","volume":"16","author":"Meulenbeld","year":"2012","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.esmoop.2024.103484_bib36","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/S1470-2045(23)00158-4","article-title":"Health-related quality of life and pain outcomes with [(177)Lu]Lu-PSMA-617 plus standard of care versus standard of care in patients with metastatic castration-resistant prostate cancer (VISION): a multicentre, open-label, randomised, phase 3 trial","volume":"6","author":"Fizazi","year":"2023","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.esmoop.2024.103484_bib37","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1111\/scd.12143","article-title":"Bisphosphonate-related osteonecrosis of the jaws: report of a case using conservative protocol","volume":"36","author":"Heggendorn","year":"2016","journal-title":"Spec Care Dentist"},{"key":"10.1016\/j.esmoop.2024.103484_bib38","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1210\/jc.2011-2353","article-title":"Androgen deprivation therapy as primary treatment for prostate cancer","volume":"2","author":"Cannata","year":"2012","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"2","key":"10.1016\/j.esmoop.2024.103484_bib39","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1038\/bjc.2013.340","article-title":"Sarcopenia and change in body composition following maximal androgen suppression with abiraterone in men with castration-resistant prostate cancer","volume":"109","author":"Pezaro","year":"2013","journal-title":"Br J Cancer"},{"key":"10.1016\/j.esmoop.2024.103484_bib40","doi-asserted-by":"crossref","first-page":"301","DOI":"10.5694\/j.1326-5377.2011.tb02979.x","article-title":"Bone and metabolic health in patients with non-metastatic prostate cancer who are receiving androgen deprivation therapy","volume":"6","author":"Grossmann","year":"2011","journal-title":"Med J Aust"},{"key":"10.1016\/j.esmoop.2024.103484_bib41","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/j.beem.2013.05.001","article-title":"Androgens and prostate cancer; pathogenesis and deprivation therapy","volume":"4","author":"Grossmann","year":"2013","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"10.1016\/j.esmoop.2024.103484_bib42","first-page":"459","article-title":"Long-term antitumor activity and safety of enzalutamide monotherapy in hormone na\u00efve prostate cancer: 3-year open label followup results","volume":"2","author":"Tombal","year":"2018","journal-title":"J\u00a0Urol"},{"key":"10.1016\/j.esmoop.2024.103484_bib43","doi-asserted-by":"crossref","first-page":"E456","DOI":"10.1210\/jc.2010-0902","article-title":"Structural decay of bone microarchitecture in men with prostate cancer treated with androgen deprivation therapy","volume":"12","author":"Hamilton","year":"2010","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"12","key":"10.1016\/j.esmoop.2024.103484_bib44","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1172\/JCI10942","article-title":"Relative contributions of testosterone and estrogen in regulating bone resorption and formation in normal elderly men","volume":"106","author":"Falahati-Nini","year":"2000","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.esmoop.2024.103484_bib45","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2023.104817","article-title":"Changes in bone and mineral homeostasis after short-term androgen deprivation therapy with or without androgen receptor signalling inhibitor - substudy of a single-centre, double blind, randomised, placebo-controlled phase 2 trial","volume":"97","author":"David","year":"2023","journal-title":"EBioMedicine"},{"issue":"23","key":"10.1016\/j.esmoop.2024.103484_bib46","doi-asserted-by":"crossref","first-page":"2187","DOI":"10.1056\/NEJMoa2004325","article-title":"Oral relugolix for androgen-deprivation therapy in advanced prostate cancer","volume":"382","author":"Shore","year":"2020","journal-title":"N\u00a0Engl J Med"},{"issue":"12","key":"10.1016\/j.esmoop.2024.103484_bib47","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1359\/jbmr.1998.13.12.1915","article-title":"Bone density and fracture risk in men","volume":"13","author":"Melton","year":"1998","journal-title":"J\u00a0Bone Miner Res"},{"key":"10.1016\/j.esmoop.2024.103484_bib48","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1038\/sj.pcan.4500599","article-title":"Androgen deprivation in men with prostate cancer is associated with an increased rate of bone loss","volume":"4","author":"Preston","year":"2002","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"10.1016\/j.esmoop.2024.103484_bib49","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1007\/s10147-016-1037-2","article-title":"A\u00a0phase III multicenter, randomized, controlled study of combined androgen blockade with versus without zoledronic acid in prostate cancer patients with metastatic bone disease: results of the ZAPCA trial","volume":"1","author":"Kamba","year":"2017","journal-title":"Int J Clin Oncol"},{"issue":"10024","key":"10.1016\/j.esmoop.2024.103484_bib50","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1016\/S0140-6736(15)01037-5","article-title":"Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial","volume":"387","author":"James","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.esmoop.2024.103484_bib51","doi-asserted-by":"crossref","first-page":"S956","DOI":"10.1016\/j.annonc.2023.09.2718","article-title":"1768MO Incidence of fracture related hospitalisations in men with de novo high risk localised and metastatic hormone sensitive prostate cancer: analysis of routinely collected healthcare data from the STAMPEDE docetaxel and zoledronic acid comparisons","volume":"34","author":"Jones","year":"2023","journal-title":"Ann Oncol"},{"issue":"suppl 1","key":"10.1016\/j.esmoop.2024.103484_bib52","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1159\/000329148","article-title":"Novel strategies for improving physical function","volume":"76","author":"Bhasin","year":"2011","journal-title":"Horm Res Paediatr"},{"issue":"12","key":"10.1016\/j.esmoop.2024.103484_bib53","doi-asserted-by":"crossref","first-page":"4594","DOI":"10.1210\/en.2013-1004","article-title":"The effects of testosterone deprivation and supplementation on proteasomal and autophagy activity in the skeletal muscle of the male mouse: differential effects on high-androgen responder and ow-androgen responder muscle groups","volume":"154","author":"Serra","year":"2013","journal-title":"Endocrinology"},{"issue":"2","key":"10.1016\/j.esmoop.2024.103484_bib54","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/j.urology.2008.03.032","article-title":"Falls and physical performance deficits in older patients with prostate cancer undergoing androgen deprivation therapy","volume":"72","author":"Bylow","year":"2008","journal-title":"Urology"},{"key":"10.1016\/j.esmoop.2024.103484_bib55","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.urolonc.2006.12.014","article-title":"Androgen deprivation therapy for prostate cancer: effects on hand function","volume":"2","author":"Soyupek","year":"2008","journal-title":"Urol Oncol"},{"key":"10.1016\/j.esmoop.2024.103484_bib56","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.2522\/ptj.20060302","article-title":"Physical function in men with prostate cancer on androgen deprivation therapy","volume":"10","author":"Clay","year":"2007","journal-title":"Phys Ther"},{"issue":"4","key":"10.1016\/j.esmoop.2024.103484_bib57","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1016\/j.urology.2010.11.024","article-title":"Obese frailty, physical performance deficits, and falls in older men with biochemical recurrence of prostate cancer on androgen deprivation therapy: a case-control study","volume":"77","author":"Bylow","year":"2011","journal-title":"Urology"},{"key":"10.1016\/j.esmoop.2024.103484_bib58","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/j.urology.2007.09.018","article-title":"Physical function changes in prostate cancer patients on androgen deprivation therapy: a 2-year prospective study","volume":"4","author":"Levy","year":"2008","journal-title":"Urology"},{"key":"10.1016\/j.esmoop.2024.103484_bib59","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1080\/13685530500361226","article-title":"The effect of 6 months of androgen deprivation therapy on muscle and fat mass in older men with localized prostate cancer","volume":"8","author":"Boxer","year":"2005","journal-title":"Aging Male"},{"key":"10.1016\/j.esmoop.2024.103484_bib60","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1007\/s40618-023-02150-z","article-title":"Heterogeneity in regional changes in body composition induced by androgen deprivation therapy in prostate cancer patients: potential impact on bone health-the BLADE study","volume":"47","author":"Dalla Volta","year":"2024","journal-title":"J\u00a0Endocrinol Invest"},{"key":"10.1016\/j.esmoop.2024.103484_bib61","doi-asserted-by":"crossref","first-page":"2361","DOI":"10.1016\/S0022-5347(05)64985-3","article-title":"Changes in bone mineral density, lean body mass and fat content as measured by dual energy x-ray absorptiometry in patients with prostate cancer without apparent bone metastases given androgen deprivation therapy","volume":"vol. 6","author":"Berruti","year":"2002","journal-title":"J Urol"},{"issue":"2","key":"10.1016\/j.esmoop.2024.103484_bib62","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1002\/jbmr.1771","article-title":"Vertebral fractures and trabecular microstructure in men with prostate cancer on androgen deprivation therapy","volume":"28","author":"Greenspan","year":"2013","journal-title":"J Bone Miner Res"},{"issue":"2-3","key":"10.1016\/j.esmoop.2024.103484_bib63","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1080\/03008200290000934","article-title":"Changes in bone remodeling rate influence the degree of mineralization of bone","volume":"43","author":"Boivin","year":"2002","journal-title":"Connect Tissue Res"},{"issue":"1","key":"10.1016\/j.esmoop.2024.103484_bib64","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1007\/s00198-018-4722-3","article-title":"Patients with prostate cancer and androgen deprivation therapy have increased risk of fractures-a study from the fractures and fall injuries in the elderly cohort (FRAILCO)","volume":"30","author":"Wallander","year":"2019","journal-title":"Osteoporos Int"},{"issue":"10","key":"10.1016\/j.esmoop.2024.103484_bib65","doi-asserted-by":"crossref","first-page":"2571","DOI":"10.1007\/s00198-013-2343-4","article-title":"Changes in bone mineral density in men starting androgen deprivation therapy and the protective role of vitamin D","volume":"24","author":"Alibhai","year":"2013","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.esmoop.2024.103484_bib66","series-title":"Fracture types and risk factors in men with prostate cancer on androgen deprivation therapy: a matched cohort study of 19,079 men. J Urol","first-page":"918","volume":"vol. 3","author":"Alibhai","year":"2010"},{"issue":"8","key":"10.1016\/j.esmoop.2024.103484_bib67","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1056\/NEJMoa0809003","article-title":"Denosumab in men receiving androgen-deprivation therapy for prostate cancer","volume":"361","author":"Smith","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.esmoop.2024.103484_bib68","first-page":"154","article-title":"Risk of fracture after androgen deprivation for prostate cancer","volume":"vol. 2","author":"Shahinian","year":"2005","journal-title":"N Engl J Med. 2005 Massachusetts Medical Society"},{"key":"10.1016\/j.esmoop.2024.103484_bib69","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.1016\/S0022-5347(05)00999-7","article-title":"Bone mineral density changes in patients with prostate cancer during the first 2 years of androgen suppression","volume":"vol. 5","author":"Morote","year":"2006","journal-title":"J Urol"},{"issue":"11","key":"10.1016\/j.esmoop.2024.103484_bib70","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1007\/s00198-007-0439-4","article-title":"Management of cancer treatment-induced bone loss in early breast and prostate cancer -- a consensus paper of the Belgian Bone Club","volume":"18","author":"Body","year":"2007","journal-title":"Osteoporos Int"},{"issue":"3","key":"10.1016\/j.esmoop.2024.103484_bib71","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1016\/j.jocd.2011.05.003","article-title":"Vertebral fractures and the misclassification of osteoporosis in men with prostate cancer","volume":"14","author":"Sullivan","year":"2011","journal-title":"J Clin Densitom"},{"issue":"27","key":"10.1016\/j.esmoop.2024.103484_bib72","doi-asserted-by":"crossref","first-page":"4426","DOI":"10.1200\/JCO.2007.15.1233","article-title":"Skeletal health after continuation, withdrawal, or delay of alendronate in men with prostate cancer undergoing androgen-deprivation therapy","volume":"26","author":"Greenspan","year":"2008","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.esmoop.2024.103484_bib73","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1111\/bju.14015","article-title":"Systematic review and network meta-analysis on the relative efficacy of osteoporotic medications: men with prostate cancer on continuous androgen-deprivation therapy to reduce risk of fragility fractures","volume":"121","author":"Poon","year":"2018","journal-title":"BJU Int"},{"key":"10.1016\/j.esmoop.2024.103484_bib74","doi-asserted-by":"crossref","DOI":"10.1155\/2018\/1525832","article-title":"The Current Role of Osteoclast Inhibitors in Patients with Prostate Cancer","volume":"2018","author":"Kozyrakis","year":"2018","journal-title":"Adv Urol"},{"key":"10.1016\/j.esmoop.2024.103484_bib75","doi-asserted-by":"crossref","first-page":"459","DOI":"10.7326\/L17-0702","article-title":"Bone Health and Bone-Targeted Therapies for Nonmetastatic Prostate Cancer","volume":"vol. 6","author":"Alibhai","year":"2018","journal-title":"Ann Intern Med"},{"issue":"12","key":"10.1016\/j.esmoop.2024.103484_bib76","first-page":"CD013020","article-title":"Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis","volume":"12","author":"Jakob","year":"2020","journal-title":"Cochrane Database Syst Rev"},{"issue":"19","key":"10.1016\/j.esmoop.2024.103484_bib77","doi-asserted-by":"crossref","DOI":"10.3390\/nu14194148","article-title":"Definition, Assessment, and Management of Vitamin D Inadequacy: Suggestions, Recommendations, and Warnings from the Italian Society for Osteoporosis, Mineral Metabolism and Bone Diseases (SIOMMMS)","volume":"14","author":"Bertoldo","year":"2022","journal-title":"Nutrients"},{"issue":"14","key":"10.1016\/j.esmoop.2024.103484_bib78","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1056\/NEJMoa1212299","article-title":"Intermittent versus continuous androgen deprivation in prostate cancer","volume":"368","author":"Hussain","year":"2013","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.esmoop.2024.103484_bib79","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1001\/jamaoncol.2015.4655","article-title":"Adverse Health Events Following Intermittent and Continuous Androgen Deprivation in Patients With Metastatic Prostate Cancer","volume":"2","author":"Hershman","year":"2016","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.esmoop.2024.103484_bib80","first-page":"21","article-title":"French recommendations for osteoporosis prevention and treatment in patients with prostate cancer treated by androgen deprivation","volume":"vol. 1","author":"Briot","year":"2019"},{"key":"10.1016\/j.esmoop.2024.103484_bib81","doi-asserted-by":"crossref","first-page":"f7524","DOI":"10.1136\/bmj.f7524","article-title":"Prostate cancer: summary of updated NICE guidance","author":"Graham","year":"2014","journal-title":"BMJ"},{"issue":"6","key":"10.1016\/j.esmoop.2024.103484_bib82","doi-asserted-by":"crossref","first-page":"2200","DOI":"10.1016\/j.juro.2010.02.022","article-title":"Application of a fracture risk algorithm to men treated with androgen deprivation therapy for prostate cancer","volume":"183","author":"Saylor","year":"2010","journal-title":"J Urol"},{"key":"10.1016\/j.esmoop.2024.103484_bib85","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbo.2022.100421","article-title":"Prediction of vertebral fractures in cancer patients undergoing hormone deprivation therapies: Reliability of who fracture risk assessment tool (frax) and bone mineral density in real-life clinical practice","volume":"33","author":"Mazziotti","year":"2022","journal-title":"J Bone Oncol"},{"key":"10.1016\/j.esmoop.2024.103484_bib86","first-page":"3398","article-title":"Effect of Degarelix Administration on Bone Health in Prostate Cancer Patients Without Bone Metastases. The Blade Study","volume":"vol. 12","author":"Palumbo","year":"2022"},{"issue":"16","key":"10.1016\/j.esmoop.2024.103484_bib87","doi-asserted-by":"crossref","DOI":"10.3390\/ijerph17165998","article-title":"Medication-Related Osteonecrosis of Jaws (MRONJ) Prevention and Diagnosis: Italian Consensus Update 2020","volume":"17","author":"Campisi","year":"2020","journal-title":"Int J Environ Res Public Health"},{"key":"10.1016\/j.esmoop.2024.103484_bib88","first-page":"2443","article-title":"Invasive Oral Procedures and Events in Postmenopausal Women With Osteoporosis Treated With Denosumab for Up to 10 Years","volume":"vol. 6","author":"Watts","year":"2019"},{"key":"10.1016\/j.esmoop.2024.103484_bib89","first-page":"756","article-title":"Denosumab for prevention of fractures in postmenopausal women with osteoporosis","volume":"vol. 8","author":"Cummings","year":"2009","journal-title":"N\u00a0Engl J Med. 2009 Massachusetts Medical Society"},{"issue":"1","key":"10.1016\/j.esmoop.2024.103484_bib90","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/s13005-021-00280-4","article-title":"A pragmatic window of opportunity to minimise the risk of MRONJ development in individuals with osteoporosis on Denosumab therapy: a hypothesis","volume":"17","author":"Campisi","year":"2021","journal-title":"Head Face Med"},{"key":"10.1016\/j.esmoop.2024.103484_bib91","series-title":"Discontinuation of Denosumab therapy for osteoporosis: A systematic review and position statement by ECTS","first-page":"11","author":"Tsourdi","year":"2017"},{"key":"10.1016\/j.esmoop.2024.103484_bib92","article-title":"Fracture risk and management of discontinuation of denosumab therapy: a systematic review and position statement by ECTS","author":"Tsourdi","year":"2020"},{"key":"10.1016\/j.esmoop.2024.103484_bib93","first-page":"45","article-title":"Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial","volume":"vol. 1","author":"Forbes","year":"2008","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.esmoop.2024.103484_bib94","first-page":"153","article-title":"Fracture incidence in pre- and postmenopausal women after completion of adjuvant hormonal therapy for breast cancer","volume":"vol. 2","author":"Koopal","year":"2015"},{"issue":"7","key":"10.1016\/j.esmoop.2024.103484_bib95","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1002\/jbmr.4298","article-title":"Prior loss of body mass index, low body mass index, and central obesity independently contribute to higher rates of fractures in elderly women and men","volume":"36","author":"Zheng","year":"2021","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.esmoop.2024.103484_bib96","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2022.981487","article-title":"The pathophysiology of osteoporosis in obesity and type 2 diabetes in aging women and men: The mechanisms and roles of increased bone marrow adiposity","volume":"13","author":"Ali","year":"2022","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"1","key":"10.1016\/j.esmoop.2024.103484_bib97","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.prnil.2018.04.002","article-title":"Sarcopenia is a poor prognostic factor of castration-resistant prostate cancer treated with docetaxel therapy","volume":"7","author":"Ohtaka","year":"2019","journal-title":"Prostate Int"},{"issue":"4","key":"10.1016\/j.esmoop.2024.103484_bib98","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1097\/JU.0000000000001873","article-title":"Sarcopenic Obesity and its Prognostic Impact on Urological Cancers: A Systematic Review","volume":"206","author":"Stangl-Kremser","year":"2021","journal-title":"J Urol"},{"issue":"1","key":"10.1016\/j.esmoop.2024.103484_bib99","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1007\/s12020-015-0525-x","article-title":"The fat body mass increase after adjuvant androgen deprivation therapy is predictive of prostate cancer outcome","volume":"50","author":"Buttigliero","year":"2015","journal-title":"Endocrine"},{"issue":"11","key":"10.1016\/j.esmoop.2024.103484_bib100","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1200\/JCO.2017.75.3657","article-title":"Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer: Long-Term Survival Analysis of the Randomized Phase III E3805 CHAARTED Trial","volume":"36","author":"Kyriakopoulos","year":"2018","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1016\/j.esmoop.2024.103484_bib101","doi-asserted-by":"crossref","first-page":"1992","DOI":"10.1093\/annonc\/mdz396","article-title":"Addition of docetaxel to hormonal therapy in low- and high-burden metastatic hormone sensitive prostate cancer: long-term survival results from the STAMPEDE trial","volume":"30","author":"Clarke","year":"2019","journal-title":"Ann Oncol"},{"issue":"9","key":"10.1016\/j.esmoop.2024.103484_bib102","doi-asserted-by":"crossref","DOI":"10.3390\/cancers11091355","article-title":"Current Treatment Options for Metastatic Hormone-Sensitive Prostate Cancer","volume":"11","author":"Cattrini","year":"2019","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.esmoop.2024.103484_bib103","first-page":"686","article-title":"Abiraterone acetate plus prednisone in patients with newly diagnosed high-risk metastatic castration-sensitive prostate cancer (LATITUDE): final overall survival analysis of a randomised, double-blind, phase 3 trial","volume":"vol. 5","author":"Fizazi","year":"2019"},{"issue":"3","key":"10.1016\/j.esmoop.2024.103484_bib104","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1002\/ijc.34018","article-title":"Abiraterone acetate plus prednisolone for metastatic patients starting hormone therapy: 5-year follow-up results from the STAMPEDE randomised trial (NCT00268476)","volume":"151","author":"James","year":"2022","journal-title":"Int J Cancer"},{"key":"10.1016\/j.esmoop.2024.103484_bib105","first-page":"719","article-title":"Abiraterone in \"High-\" and \"Low-risk\" Metastatic Hormone-sensitive Prostate Cancer","volume":"vol. 6","author":"Hoyle","year":"2019"},{"issue":"2","key":"10.1016\/j.esmoop.2024.103484_bib106","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1056\/NEJMoa1903835","article-title":"Enzalutamide with Standard First-Line Therapy in Metastatic Prostate Cancer","volume":"381","author":"Davis","year":"2019","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.esmoop.2024.103484_bib107","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1056\/NEJMoa1903307","article-title":"Apalutamide for Metastatic, Castration-Sensitive Prostate Cancer","volume":"381","author":"Chi","year":"2019","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.esmoop.2024.103484_bib108","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1056\/NEJMoa2119115","article-title":"Darolutamide and Survival in Metastatic, Hormone-Sensitive Prostate Cancer","volume":"386","author":"Smith","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.esmoop.2024.103484_bib109","doi-asserted-by":"crossref","first-page":"v69","DOI":"10.1093\/annonc\/mdv222","article-title":"Cancer of the prostate: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","author":"Parker","year":"2015","journal-title":"Ann Oncol"},{"issue":"2","key":"10.1016\/j.esmoop.2024.103484_bib110","doi-asserted-by":"crossref","DOI":"10.1136\/esmoopen-2019-000652","article-title":"Bone health management in the continuum of prostate cancer disease: a review of the evidence with an expert panel opinion","volume":"5","author":"Santini","year":"2020","journal-title":"ESMO Open"},{"issue":"11","key":"10.1016\/j.esmoop.2024.103484_bib111","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1200\/JCO.2013.51.6500","article-title":"Randomized controlled trial of early zoledronic acid in men with castration-sensitive prostate cancer and bone metastases: results of CALGB 90202 (alliance)","volume":"32","author":"Smith","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.esmoop.2024.103484_bib112","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1007\/s10147-016-1037-2","article-title":"A phase III multicenter, randomized, controlled study of combined androgen blockade with versus without zoledronic acid in prostate cancer patients with metastatic bone disease: results of the ZAPCA trial","volume":"vol. 1","author":"Kamba","year":"2017","journal-title":"Int J Clin Oncol"},{"issue":"10024","key":"10.1016\/j.esmoop.2024.103484_bib113","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1016\/S0140-6736(15)01037-5","article-title":"Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial","volume":"387","author":"James","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.esmoop.2024.103484_bib114","doi-asserted-by":"crossref","first-page":"S956","DOI":"10.1016\/j.annonc.2023.09.2718","article-title":"1768MO Incidence of fracture related hospitalisations in men with de novo high risk localised and metastatic hormone sensitive prostate cancer: Analysis of routinely collected healthcare data from the STAMPEDE docetaxel and zoledronic acid comparisons","volume":"34","author":"Jones","year":"2023","journal-title":"Annals of Oncology"},{"issue":"3","key":"10.1016\/j.esmoop.2024.103484_bib115","doi-asserted-by":"crossref","first-page":"232","DOI":"10.7150\/jca.13403","article-title":"Vitamin D and Colorectal, Breast, and Prostate Cancers: A Review of the Epidemiological Evidence","volume":"7","author":"Jacobs","year":"2016","journal-title":"J Cancer"},{"key":"10.1016\/j.esmoop.2024.103484_bib116","first-page":"1447","article-title":"Vitamin D in blood and risk of prostate cancer: lessons from the Selenium and Vitamin E Cancer Prevention Trial and the\u00a0Prostate Cancer Prevention Trial","volume":"vol. 8","author":"Schwartz","year":"2014"},{"issue":"6","key":"10.1016\/j.esmoop.2024.103484_bib117","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1111\/cen.14169","article-title":"Hypocalcaemia following denosumab in prostate cancer: A clinical review","volume":"92","author":"Lau","year":"2020","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"43","key":"10.1016\/j.esmoop.2024.103484_bib118","doi-asserted-by":"crossref","first-page":"75646","DOI":"10.18632\/oncotarget.17980","article-title":"The prevention of fragility fractures in patients with non-metastatic prostate cancer: a position statement by the international osteoporosis foundation","volume":"8","author":"Cianferotti","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.esmoop.2024.103484_bib119","first-page":"18","article-title":"The clinical effectiveness of denosumab (Prolia\u00ae) in patients with hormone-sensitive cancer receiving endocrine therapy, compared to bisphosphonates, selective estrogen receptor modulators (SERM), and placebo: a systematic review and network meta-analysis","volume":"vol. 1","author":"Nicolopoulos","year":"2023"},{"key":"10.1016\/j.esmoop.2024.103484_bib120","series-title":"Mechanisms of resistance to systemic therapy in metastatic castration-resistant prostate cancer. Cancer Treat Rev","first-page":"16","author":"Galletti","year":"2017"},{"key":"10.1016\/j.esmoop.2024.103484_bib121","series-title":"Targeting androgen-independent pathways: new chances for patients with prostate cancer? Crit Rev Oncol Hematol","first-page":"42","author":"Cattrini","year":"2017"},{"issue":"11","key":"10.1016\/j.esmoop.2024.103484_bib122","doi-asserted-by":"crossref","first-page":"2393","DOI":"10.1002\/cncr.23473","article-title":"Antiandrogen withdrawal in castrate-refractory prostate cancer: a Southwest Oncology Group trial (SWOG 9426)","volume":"112","author":"Sartor","year":"2008","journal-title":"Cancer"},{"key":"10.1016\/j.esmoop.2024.103484_bib123","first-page":"1189","article-title":"Salvage therapy with bicalutamide 150 mg in nonmetastatic castration-resistant prostate cancer","volume":"vol. 5","author":"Lodde","year":"2010"},{"key":"10.1016\/j.esmoop.2024.103484_bib124","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1016\/j.juro.2008.05.045","article-title":"Alternative nonsteroidal antiandrogen therapy for advanced prostate cancer that relapsed after initial maximum androgen blockade","volume":"vol. 3","author":"Suzuki","year":"2008","journal-title":"J Urol"},{"key":"10.1016\/j.esmoop.2024.103484_bib125","first-page":"956","article-title":"Androgen Receptor Targeted Treatments of Prostate Cancer: 35 Years of Progress with Antiandrogens","volume":"vol. 5","author":"Crawford","year":"2018"},{"issue":"15","key":"10.1016\/j.esmoop.2024.103484_bib126","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1056\/NEJMoa1715546","article-title":"Apalutamide Treatment and Metastasis-free Survival in Prostate Cancer","volume":"378","author":"Smith","year":"2018","journal-title":"N Engl J Med"},{"issue":"26","key":"10.1016\/j.esmoop.2024.103484_bib127","doi-asserted-by":"crossref","first-page":"2465","DOI":"10.1056\/NEJMoa1800536","article-title":"Enzalutamide in Men with Nonmetastatic, Castration-Resistant Prostate Cancer","volume":"378","author":"Hussain","year":"2018","journal-title":"N Engl J Med"},{"issue":"13","key":"10.1016\/j.esmoop.2024.103484_bib128","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1056\/NEJMoa1815671","article-title":"Darolutamide in Nonmetastatic, Castration-Resistant Prostate Cancer","volume":"380","author":"Fizazi","year":"2019","journal-title":"N Engl J Med"},{"issue":"9810","key":"10.1016\/j.esmoop.2024.103484_bib129","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S0140-6736(11)61226-9","article-title":"Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: results of a phase 3, randomised, placebo-controlled trial","volume":"379","author":"Smith","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.esmoop.2024.103484_bib131","first-page":"286","article-title":"Efficacy and safety of enzalutamide in patients 75 years or older with chemotherapy-naive metastatic castration-resistant prostate cancer: results from PREVAIL","volume":"vol. 2","author":"Graff","year":"2016"},{"issue":"13","key":"10.1016\/j.esmoop.2024.103484_bib132","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1056\/NEJMoa1207506","article-title":"Increased survival with enzalutamide in prostate cancer after chemotherapy","volume":"367","author":"Scher","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.esmoop.2024.103484_bib133","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2019.37.7_suppl.156","article-title":"Higher blood\u2013brain barrier penetration of [ 14 C]apalutamide and [ 14 C]enzalutamide compared to [ 14 C]darolutamide in rats using whole-body autoradiography","volume":"37","author":"Zurth","year":"2019","journal-title":"Journal of Clinical Oncology"},{"key":"10.1016\/j.esmoop.2024.103484_bib134","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/S0897-1897(95)80592-3","article-title":"Hospital falls: development of a predictive model for clinical practice","author":"Hendrich","year":"1995","journal-title":"Appl Nurs Res"},{"key":"10.1016\/j.esmoop.2024.103484_bib135","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1053\/apnr.2003.016009","article-title":"Validation of the Hendrich II Fall Risk Model: a large concurrent case\/control study of hospitalized patients","volume":"vol. 1","author":"Hendrich","year":"2003","journal-title":"Appl Nurs Res. Elsevier Science (USA)"},{"issue":"9","key":"10.1016\/j.esmoop.2024.103484_bib136","doi-asserted-by":"crossref","first-page":"3681","DOI":"10.1007\/s00520-016-3312-1","article-title":"Fall-risk prediction in older adults with cancer: an unmet need","volume":"24","author":"Wildes","year":"2016","journal-title":"Support Care Cancer"},{"issue":"6","key":"10.1016\/j.esmoop.2024.103484_bib137","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1002\/jbmr.3972","article-title":"A Pooled Analysis of Fall Incidence From Placebo-Controlled Trials of Denosumab","volume":"35","author":"Chotiyarnwong","year":"2020","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.esmoop.2024.103484_bib138","first-page":"513","article-title":"10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension","volume":"vol. 7","author":"Bone","year":"2017"},{"issue":"2","key":"10.1016\/j.esmoop.2024.103484_bib139","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2022.e11880","article-title":"Efficacy and safety of pharmacologic therapies for prevention of osteoporotic vertebral fractures in postmenopausal women","volume":"9","author":"Wei","year":"2023","journal-title":"Heliyon"},{"issue":"6","key":"10.1016\/j.esmoop.2024.103484_bib140","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1002\/jbmr.3110","article-title":"Clinical Features of 24 Patients With Rebound-Associated Vertebral Fractures After Denosumab Discontinuation: Systematic Review and Additional Cases","volume":"32","author":"Anastasilakis","year":"2017","journal-title":"J Bone Miner Res"},{"issue":"4","key":"10.1016\/j.esmoop.2024.103484_bib141","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1002\/jbmr.1808","article-title":"Discontinuation of denosumab and associated fracture incidence: analysis from the Fracture Reduction Evaluation of Denosumab in Osteoporosis Every 6 Months (FREEDOM) trial","volume":"28","author":"Brown","year":"2013","journal-title":"J Bone Miner Res"},{"issue":"25","key":"10.1016\/j.esmoop.2024.103484_bib142","doi-asserted-by":"crossref","first-page":"2407","DOI":"10.1056\/NEJMoa1808082","article-title":"Fracture Prevention with Zoledronate in Older Women with Osteopenia","volume":"379","author":"Reid","year":"2018","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.esmoop.2024.103484_bib143","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1007\/s00520-008-0418-0","article-title":"Impact of skeletal complications on patients' quality of life, mobility, and functional independence","volume":"16","author":"Costa","year":"2008","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.esmoop.2024.103484_bib144","series-title":"Examining the metastatic niche: targeting the microenvironment. Semin Oncol. \u00a9 2010","first-page":"S2","author":"Guise","year":"2010"},{"key":"10.1016\/j.esmoop.2024.103484_bib145","first-page":"165","article-title":"Metastatic bone disease: clinical features, pathophysiology and treatment strategies","volume":"vol. 3.","author":"Coleman","year":"2001","journal-title":"Cancer Treat Rev. 2001 Harcourt Publishers Ltd"},{"key":"10.1016\/j.esmoop.2024.103484_bib146","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1093\/annonc\/mdi122","article-title":"The significance of skeletal-related events for the health-related quality of life of patients with metastatic prostate cancer","volume":"vol. 4","author":"Weinfurt","year":"2005","journal-title":"Ann Oncol"},{"key":"10.1016\/j.esmoop.2024.103484_bib147","first-page":"597","article-title":"Health-related quality of life and pain outcomes with [(177)Lu]Lu-PSMA-617 plus standard of care versus standard of care in patients with metastatic castration-resistant prostate cancer (VISION): a multicentre, open-label, randomised, phase 3 trial","author":"Fizazi","year":"2023"},{"issue":"32","key":"10.1016\/j.esmoop.2024.103484_bib148","doi-asserted-by":"crossref","first-page":"3763","DOI":"10.1200\/JCO.20.01035","article-title":"Rucaparib in Men With Metastatic Castration-Resistant Prostate Cancer Harboring a BRCA1 or BRCA2 Gene Alteration","volume":"38","author":"Abida","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.esmoop.2024.103484_bib149","first-page":"1502","article-title":"Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer","volume":"vol. 15","author":"Tannock","year":"2004","journal-title":"N Engl J Med. 2004 Massachusetts Medical Society"},{"key":"10.1016\/j.esmoop.2024.103484_bib150","first-page":"1513","article-title":"Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer","volume":"vol. 15","author":"Petrylak","year":"2004","journal-title":"N Engl J Med. 2004 Massachusetts Medical Society"},{"issue":"2","key":"10.1016\/j.esmoop.2024.103484_bib151","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1056\/NEJMoa1209096","article-title":"Abiraterone in metastatic prostate cancer without previous chemotherapy","volume":"368","author":"Ryan","year":"2013","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.esmoop.2024.103484_bib152","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1056\/NEJMoa1405095","article-title":"Enzalutamide in metastatic prostate cancer before chemotherapy","volume":"371","author":"Beer","year":"2014","journal-title":"N Engl J Med"},{"issue":"21","key":"10.1016\/j.esmoop.2024.103484_bib153","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1014618","article-title":"Abiraterone and increased survival in metastatic prostate cancer","volume":"364","author":"de Bono","year":"2011","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.esmoop.2024.103484_bib154","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1056\/NEJMoa1213755","article-title":"Alpha emitter radium-223 and survival in metastatic prostate cancer","volume":"369","author":"Parker","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.esmoop.2024.103484_bib155","first-page":"408","article-title":"Addition of radium-223 to abiraterone acetate and prednisone or prednisolone in patients with castration-resistant prostate cancer and bone metastases (ERA 223): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"vol. 3","author":"Smith","year":"2019"},{"key":"10.1016\/j.esmoop.2024.103484_bib157","first-page":"243","article-title":"EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer-2020 Update. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent","volume":"vol. 2","author":"Mottet","year":"2021"},{"key":"10.1016\/j.esmoop.2024.103484_bib158","first-page":"227","article-title":"The effects of enzalutamide and abiraterone on skeletal related events and bone radiological progression free survival in castration resistant prostate cancer patients: An indirect comparison of randomized controlled trials","author":"Rizzo","year":"2017"},{"issue":"15_suppl","key":"10.1016\/j.esmoop.2024.103484_bib159","article-title":"Real world skeletal related events (SREs) associated with oral treatments in patients with metastatic castration resistant prostate cancer (mCRPC)","volume":"34","author":"Engel-Nitz","year":"2023","journal-title":"Journal of Clinical Oncology"},{"issue":"4","key":"10.1016\/j.esmoop.2024.103484_bib160","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1016\/j.eururo.2015.04.032","article-title":"Impact of bone-targeted therapies in chemotherapy-na\u00efve metastatic castration-resistant prostate cancer patients treated with abiraterone acetate: post hoc analysis of study COU-AA-302","volume":"68","author":"Saad","year":"2015","journal-title":"Eur Urol"},{"issue":"9768","key":"10.1016\/j.esmoop.2024.103484_bib161","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1016\/S0140-6736(10)62344-6","article-title":"Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study","volume":"377","author":"Fizazi","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.esmoop.2024.103484_bib162","first-page":"3837","article-title":"Efficacy of combined androgen blockade with zoledronic acid treatment in prostate cancer with bone metastasis: the ZABTON-PC (zoledronic acid\/androgen blockade trial on prostate cancer) study","volume":"vol. 9","author":"Ueno","year":"2013","journal-title":"Anticancer Res"},{"key":"10.1016\/j.esmoop.2024.103484_bib163","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbo.2020.100339","article-title":"Real-world practice patterns and attitudes towards de-escalation of bone-modifying agents in patients with bone metastases from breast and prostate cancer: A physician survey","volume":"26","author":"AlZahrani","year":"2021","journal-title":"J Bone Oncol"},{"issue":"6","key":"10.1016\/j.esmoop.2024.103484_bib164","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1007\/s00520-017-3583-1","article-title":"Longitudinal patterns of bone-targeted agent use among patients with solid tumors and bone metastases in the United States","volume":"25","author":"Qian","year":"2017","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.esmoop.2024.103484_bib165","first-page":"284","article-title":"Treatment Patterns and Outcomes in Patients With Metastatic Castration-resistant Prostate Cancer in a Real-world Clinical Practice Setting in the United States","volume":"vol. 4","author":"George","year":"2020"},{"key":"10.1016\/j.esmoop.2024.103484_bib166","first-page":"1147","article-title":"Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial","volume":"vol. 9747","author":"de Bono","year":"2010"},{"issue":"24","key":"10.1016\/j.esmoop.2024.103484_bib167","doi-asserted-by":"crossref","first-page":"2345","DOI":"10.1056\/NEJMoa2022485","article-title":"Survival with Olaparib in Metastatic Castration-Resistant Prostate Cancer","volume":"383","author":"Hussain","year":"2020","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.esmoop.2024.103484_bib168","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1186\/s13018-021-02554-8","article-title":"Comparison of denosumab and zoledronic acid for the treatment of solid tumors and multiple myeloma with bone metastasis: a systematic review and meta-analysis based on randomized controlled trials","volume":"16","author":"Jiang","year":"2021","journal-title":"J Orthop Surg Res"},{"key":"10.1016\/j.esmoop.2024.103484_bib169","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbo.2018.100212","article-title":"A real-world study assessing the use of bone-targeted agents and their impact on bone metastases in patients with prostate cancer treated in clinical practice in Europe","volume":"14","author":"Body","year":"2019","journal-title":"J Bone Oncol"},{"key":"10.1016\/j.esmoop.2024.103484_bib170","first-page":"663","article-title":"Efficacy and safety of 12-weekly versus 4-weekly zoledronic acid for prolonged treatment of patients with bone metastases from breast cancer (ZOOM): a phase 3, open-label, randomised, non-inferiority trial","volume":"vol. 7","author":"Amadori","year":"2013"},{"key":"10.1016\/j.esmoop.2024.103484_bib171","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbo.2021.100388","article-title":"Two-year results of a randomised trial comparing 4- versus 12-weekly bone-targeted agent use in patients with bone metastases from breast or castration-resistant prostate cancer","volume":"30","author":"Clemons","year":"2021","journal-title":"J Bone Oncol"},{"key":"10.1016\/j.esmoop.2024.103484_bib172","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.1200\/JCO.2008.19.2146","article-title":"Randomized phase II trial of denosumab in patients with bone metastases from prostate cancer, breast cancer, or other neoplasms after intravenous bisphosphonates","volume":"vol. 10","author":"Fizazi","year":"2009","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.esmoop.2024.103484_bib173","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1007\/s00280-021-04262-w","article-title":"Switching from zoledronic acid to denosumab increases the risk for developing medication-related osteonecrosis of the jaw in patients with bone metastases","volume":"87","author":"Ikesue","year":"2021","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.esmoop.2024.103484_bib174","first-page":"2993","article-title":"Randomised phase II\/III study of docetaxel with or without risedronate in patients with metastatic Castration Resistant Prostate Cancer (CRPC), the Netherlands Prostate Study (NePro)","volume":"vol. 16","author":"Meulenbeld","year":"2012"},{"key":"10.1016\/j.esmoop.2024.103484_bib175","doi-asserted-by":"crossref","first-page":"3335","DOI":"10.1200\/JCO.2003.03.042","article-title":"Randomized, double-blind, controlled trial of mitoxantrone\/prednisone and clodronate versus mitoxantrone\/prednisone and placebo in patients with hormone-refractory prostate cancer and pain","volume":"vol. 17","author":"Ernst","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.esmoop.2024.103484_bib176","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/S0022-5347(17)40597-0","article-title":"Palliation of painful bone metastases from prostate cancer using sodium etidronate: results of a randomized, prospective, double-blind, placebo-controlled study","volume":"vol. 1","author":"Smith","year":"1989","journal-title":"J Urol"},{"issue":"12","key":"10.1016\/j.esmoop.2024.103484_bib177","first-page":"CD006250","article-title":"Bisphosphonates for advanced prostate cancer","volume":"12","author":"Macherey","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"issue":"19","key":"10.1016\/j.esmoop.2024.103484_bib178","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1093\/jnci\/94.19.1458","article-title":"A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma","volume":"94","author":"Saad","year":"2002","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.esmoop.2024.103484_bib180","first-page":"491","article-title":"Bisphosphonate effects on the behaviour of oral epithelial cells and oral fibroblasts","volume":"vol. 5","author":"Ravosa","year":"2011"},{"issue":"2","key":"10.1016\/j.esmoop.2024.103484_bib181","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1002\/hed.21708","article-title":"Factors influencing surgical treatment of bisphosphonate-related osteonecrosis of the jaws","volume":"34","author":"Wutzl","year":"2012","journal-title":"Head Neck"},{"issue":"1","key":"10.1016\/j.esmoop.2024.103484_bib182","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1111\/scd.12143","article-title":"Bisphosphonate-related osteonecrosis of the jaws: Report of a case using conservative protocol","volume":"36","author":"Heggendorn","year":"2016","journal-title":"Spec Care Dentist"},{"key":"10.1016\/j.esmoop.2024.103484_bib183","first-page":"1938","article-title":"American Association of Oral and Maxillofacial Surgeons position paper on medication-related osteonecrosis of the jaw--2014 update","volume":"vol. 10","author":"Ruggiero","year":"2014"},{"key":"10.1016\/j.esmoop.2024.103484_bib184","first-page":"930","article-title":"Conservative surgical management of patients with bisphosphonate-related osteonecrosis of the jaws: a series of 120 patients. Br J Oral Maxillofac Surg","volume":"vol. 8","author":"Nisi","year":"2016"}],"container-title":["ESMO Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702924012535?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702924012535?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,7,31]],"date-time":"2024-07-31T00:44:43Z","timestamp":1722386683000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2059702924012535"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7]]},"references-count":177,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2024,7]]}},"alternative-id":["S2059702924012535"],"URL":"https:\/\/doi.org\/10.1016\/j.esmoop.2024.103484","relation":{},"ISSN":["2059-7029"],"issn-type":[{"value":"2059-7029","type":"print"}],"subject":[],"published":{"date-parts":[[2024,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Bone health and body composition in prostate cancer: Meet-URO and AIOM consensus about prevention and management strategies","name":"articletitle","label":"Article Title"},{"value":"ESMO Open","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.esmoop.2024.103484","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier Ltd on behalf of European Society for Medical Oncology.","name":"copyright","label":"Copyright"}],"article-number":"103484"}}